Volume 5.30 | Aug 15

Prostate Cell News 5.30 August 15, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PCN on Twitter
Arrestin2 Modulates Androgen Receptor Activation
Researchers report that arrestin2 functions as a positive regulator of androgen receptor expression and function in prostate cancer cells. [Oncogene] Abstract
ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays - FREE Sample Request
PUBLICATIONS (Ranked by impact factor of the journal)

Prostate Cancer Cell Response to Paclitaxel Is Affected by Abnormally Expressed Securin PTTG1
By using two prostate cancer cell lines with different responses to paclitaxel treatment, scientists identified two situations in which PTTG1 influences cell fate differentially. [Mol Cancer Ther] Abstract

Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer
Combinatorial treatments using Etomoxir and Orlistat resulted in synergistic decreased viability in LNCaP, VCaP and patient-derived benign and prostate cancer cells. These effects were associated with decreased androgen receptor expression, decreased mammalian target of rapamycin signaling and increased caspase-3 activation. [Mol Cancer Ther] Abstract

RAD9 Enhances Radioresistance of Human Prostate Cancer Cells through Regulation of ITGB1 Protein Levels
Scientists previously showed that RAD9 downregulation in human prostate cancer cells reduces integrin β1 (ITGB1) protein levels and ectopic expression of Mrad9 restores inherent high levels. They now use RNA interference to knockdown Rad9 expression in PC3 and DU145 prostate cancer cells. [Prostate] Abstract

Down-Modulation of Bcl-2 Sensitizes PTEN-Mutated Prostate Cancer Cells to Starvation and Taxanes
Researchers assessed the sensitivity of different prostate cancer cell lines to starvation and observed a differential response correlated to the levels of Akt activation. The four prostate cancer cell lines also showed different sensitivity to taxol treatments; LNCaP and 22Rv1 cells were more resistant to paclitaxel than DU145 and PC3 cells. [Prostate] Abstract

Subverting ER-Stress towards Apoptosis by Nelfinavir and Curcumin Coexposure Augments Docetaxel Efficacy in Castration Resistant Prostate Cancer Cells
In a castration resistant prostate cancer cell line, C4-2B, researchers observed significant enhancement of docetaxel-induced cytotoxicity following coexposure to thapsigargin and an AKT-inhibitor. [PLoS One]
Full Article

Overexpression of Oxidored-Nitro Domain Containing Protein 1 Induces Growth Inhibition and Apoptosis in Human Prostate Cancer PC3 Cells
Researchers investigated the function and mechanism of oxidored-nitro domain containing protein 1 in prostate cancer PC3 cells. DU145 and PC3 cells were transduced with a vector and cell viability, proliferation and apoptosis were determined. [Oncol Rep] Abstract

Synthesis and Cytotoxic Activity Evaluation of Novel Arylpiperazine Derivatives on Human Prostate Cancer Cell Lines
A series of novel arylpiperazine derivatives was synthesized. The in vitro cytotoxic activities of all synthesized compounds against three human prostate cancer cell lines were evaluated by a CCK-8 assay. [Molecules] Abstract | Download Full Article

α-Solanine Inhibits Invasion of Human Prostate Cancer Cell by Suppressing Epithelial-Mesenchymal Transition and MMPs Expression
Scientists investigated the suppression mechanism of α-solanine on motility of the human prostate cancer cell PC-3. They show that α-solanine reduces the viability of PC-3 cells. [Molecules]
Abstract | Download Full Article


Screening and Prostate Cancer Mortality: Results of the European Randomized Study of Screening for Prostate Cancer (ERSPC) at 13 Years of Follow-Up
The ERSPC has shown significant reductions in prostate cancer mortality after 9 years and 11 years of follow-up, but screening is controversial because of adverse events such as overdiagnosis. The authors provide updated results of mortality from prostate cancer with follow-up to 2010, with analyses truncated at 9, 11, and 13 years. [Lancet] Abstract

Phase I Study of Abiraterone Acetate in Chemotherapy-Naïve Japanese Patients with Castration-Resistant Prostate Cancer
Abiraterone acetate, the prodrug of abiraterone, which is an inhibitor of androgen synthesis enzymes, was evaluated for pharmacokinetics, pharmacodynamics, preliminary efficacy and safety in Japanese patients with castration-resistant prostate cancer in a Phase I, open-label and dose-escalation study. [Cancer Sci] Abstract

Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.
Strategies for Targeting the Androgen Receptor Axis in Prostate Cancer
The author discusses the mechanisms promoting androgen receptor (AR) signaling and the development of second-generation therapeutics targeting AR in castrate-resistant prostate cancer. [Drug Discov Today] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
National Cancer Institute Awards $7.3 Million to Kaiser Permanente for Cancer Clinical Trials, Patient Care Research
A new five-year, $7.3 million award from the National Cancer Institute will allow Kaiser Permanente to expand its cancer clinical trials program. [Kaiser Permanente] Press Release

Cancer Research UK Launches Scheme to Bring Together Engineers, Physicists and Biologists
A new funding scheme launched by Cancer Research UK looks to bring new insight to some of cancer’s biggest challenges. The Cancer Research UK Multidisciplinary Project Award will fund projects that encourage collaborations between cancer researchers and scientists from the engineering and physical sciences. [Cancer Research UK] Press Release

From our sponsor:
Interested in assays for human mammary stem and progenitor cells?
Request your free wallchart.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 21st Stem Cell Network Workshop – Bioengineering and Stem Cells
September 23, 2014
Sydney, Australia

Visit our events page to see a complete list of events in the prostate cell community.
NEW Postdoctoral Fellow – Prostate Cancer (Cleveland Clinic)

Postdoctoral Position – Molecular Physiology in Prostate Cancer (Duke Molecular Physiology Institute)

Senior Researcher – Interactions between Signaling Pathways of Cytokines, Growth Factors and Androgen Receptors (International Clinical Research Center – St. Anne’s University Hospital)

Postdoctoral Fellow – Cancer and miR Biology (Thomas Jefferson University Hospital)

PhD Position – Prostate Cancer Research (Institute of Oncology Research)

Postdoctoral Position – Cancer Biology/Genomics (Cornell University)

Postdoctoral Research Fellow – Mechanism of Gene Regulation in Prostate Cancer Development and Bone Metastasis (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Fellow – Computational Biology (Netherlands Cancer Institute)

Postdoctoral Fellow – Prostate Cancer Research (Institute of Oncology Research)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us